Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLINDA: Fixed-dose Olmesartan + Indapamide for Hypertension
NCT05110898Phase 3Unknown
- Sponsor
- Brainfarma
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of olmesartan, indapamide in essential hypertension, sponsored by Brainfarma. Status: unknown.
02
Drugs
olmesartanindapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05110898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110898.